Evidence map›Paper›PMID 32176025›Full record

ArticleMedicine2020

SIRT2 expression exhibits potential to serve as a biomarker for disease surveillance and prognosis in the management of cervical cancer patients.

Li-Ping Yang, Hai-Qin Feng, Jian-Cai Ma, Hong Wu, Cai-Ru Liu, Jun-de Hou

Abstract read
In one paragraph

Article in Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Sirtuin 1 and Sirtuin 2 Gene Expressions in Colorectal Cancers.Journal of clinical practice and research · 2025
    Article
  2. Article
  3. The sirtuin family in health and disease.Signal transduction and targeted therapy · 2022
    Review
  4. Role of sirtuins in esophageal cancer: Current status and future prospects.World journal of gastrointestinal oncology · 2022
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Li-Ping YangDepartment of Gynaecology and Obstetrics.
Hai-Qin FengDepartment of Gynaecology and Obstetrics.
Jian-Cai MaDepartment of Gynaecology and Obstetrics.
Hong WuDepartment of Gynaecology and Obstetrics.
Cai-Ru LiuDepartment of Gynaecology and Obstetrics.
Jun-de HouDepartment of Anesthesiology, HanDan Central Hospital, Handan 056008, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to compare the sirtuin 2 (SIRT2) expression between tumor tissue and adjacent tissue, and to investigate the association of tumor SIRT2 expression with clinical characteristics and survival profiles in cervical cancer patients.One hundred ninety-one cervical cancer patients were reviewed in this retrospective study. All patients underwent surgical resection and had well-preserved tumor tissue and adjacent tissue, which were obtained for SIRT2 expression detection by immunohistochemistry (IHC). Clinical parameters were obtained. Disease free survival (DFS) and overall survival (OS) were calculated.Both SIRT2 expression by IHC score (P < .001) and the percentage of SIRT2 high expression (defined as IHC score >3) (P < .001) were declined in tumor tissue compared with paired adjacent tissue. In addition, SIRT2 expression in tumor tissue was negatively correlated with tumor size (P = .047), lymph node metastasis (P = .009) and FIGO stage (P = .001). And the DFS (P = .007) as well as OS (P = .008) were better in patients with SIRT2 high expression compared with patents with SIRT2 low expression. Univariate Cox's proportional hazards regression model analyses revealed that high SIRT2 expression in tumor tissue was a predictive factor for more prolonged DFS (P = .009) and OS (P = .011), while multivariate Cox's proportional hazards regression model analysis disclosed that it lacks independent predictive value for DFS (P = .084) or OS (P = .132).SIRT2 expression exhibits potential to serve as a biomarker for disease surveillance and prognosis in the management of cervical cancer patients.

Indexed as

AdultBiomarkers, TumorCervix UteriDisease-Free SurvivalFemaleHumansMiddle AgedPrognosisProportional Hazards ModelsRetrospective StudiesSirtuin 2Survival AnalysisUterine Cervical NeoplasmsBiomarkers, TumorSIRT2 protein, humanSirtuin 2

Identifiers

PMID32176025
PMCPMC7440089

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.